CA
NZ
UK
AU
IND
US
…
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on Talphera Inc. (TLPH) is limited, so its core business, product pipeline, and strategy are not well-documented in widely available sources. Investors may find the company of interest if it issues clearer disclosures, demonstrates commercial traction or secures partnerships or financing that could support long-term growth, and should review SEC filings and company communications for material updates before drawing conclusions.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -14.36M | -13.00M | -10.29M | 59.14M | -35.09M |
| Net income | -14.29M | -13.00M | -18.40M | 47.76M | -35.10M |
| Selling general administrative | 7.48M | 8.53M | 11.99M | 17.01M | 30.93M |
| Gross profit | 0.03M | -6.72M | 0.34M | -0.82M | -0.94M |
| Reconciled depreciation | - | 0.00M | 0.31M | 1.65M | 1.97M |
| Ebit | - | -12.61M | -10.15M | -18.85M | -32.80M |
| Ebitda | -14.36M | -12.51M | -9.84M | -17.20M | -30.83M |
| Depreciation and amortization | - | 0.10M | 0.31M | 1.65M | 1.97M |
| Operating income | -13.48M | -15.25M | -16.89M | -25.30M | -35.97M |
| Other operating expenses | 13.51M | 15.25M | 17.54M | 20.35M | 38.78M |
| Interest expense | 0.00M | 0.39M | 0.13M | 1.12M | 2.29M |
| Tax provision | - | - | 0.00M | 0.01M | 0.01M |
| Interest income | 0.44M | 0.68M | 6.74M | 1.50M | 3.16M |
| Net interest income | 0.44M | 0.28M | 6.60M | 0.39M | 0.87M |
| Income tax expense | - | - | 14.85M | 0.01M | 0.01M |
| Total revenue | 0.03M | 0.00M | 0.65M | 1.77M | 2.82M |
| Total operating expenses | 13.51M | 8.53M | 17.54M | 20.35M | 35.03M |
| Cost of revenue | - | 6.72M | 0.31M | 2.59M | 3.75M |
| Total other income expense net | -0.88M | 2.25M | 6.60M | 79.10M | 0.87M |
| Net income from continuing ops | -14.36M | -13.00M | -10.29M | 59.12M | -35.10M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 29.72M | 18.24M | 20.39M | 47.49M | 77.89M |
| Intangible assets | 8.82M | 8.82M | 8.82M | 8.82M | - |
| Other current assets | 0.52M | 0.55M | 2.17M | 1.86M | 2.59M |
| Total liab | 12.68M | 10.24M | 6.29M | 25.67M | 113.79M |
| Total stockholder equity | 17.04M | 8.00M | 14.11M | 21.81M | -35.89M |
| Other current liab | 3.27M | 1.98M | 3.18M | 7.04M | 6.44M |
| Common stock | 0.05M | 0.02M | 0.02M | 0.01M | 0.01M |
| Capital stock | 0.05M | 0.02M | 0.02M | 0.01M | 0.01M |
| Retained earnings | -471.52M | -457.23M | -444.23M | -425.83M | -473.58M |
| Cash | 5.89M | 8.86M | 5.72M | 15.28M | 7.66M |
| Total current liabilities | 3.81M | 2.65M | 4.51M | 13.77M | 18.51M |
| Current deferred revenue | - | - | - | 0.12M | 0.09M |
| Net debt | 0.60M | -2.34M | -5.72M | -9.91M | 10.96M |
| Short term debt | - | - | - | 5.36M | 9.86M |
| Short long term debt | - | - | - | 5.36M | 8.80M |
| Short long term debt total | 6.50M | 6.53M | - | 5.36M | 18.62M |
| Other stockholder equity | 488.51M | 465.21M | 458.31M | 447.63M | 437.68M |
| Total current assets | 20.90M | 9.42M | 11.56M | 24.57M | 50.49M |
| Short term investments | 14.49M | 0.00M | 3.66M | 0.49M | 38.97M |
| Net receivables | - | - | - | 0.31M | 0.16M |
| Long term debt | - | - | - | - | 5.01M |
| Inventory | - | - | - | 1.18M | 1.11M |
| Accounts payable | 0.54M | 0.67M | 1.34M | 1.26M | 2.12M |
| Non currrent assets other | 8.82M | 8.82M | 0.02M | 0.25M | 7.17M |
| Non current assets total | 8.82M | 8.82M | 8.84M | 22.92M | 27.40M |
| Capital lease obligations | - | - | - | 4.66M | 4.82M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -14.35M | 3.78M | -0.53M | 36.45M | -26.12M |
| Total cashflows from investing activities | -14.35M | 3.78M | - | - | - |
| Net borrowings | - | 0.00M | - | - | - |
| Total cash from financing activities | 22.74M | 12.04M | 3.47M | -0.51M | 41.51M |
| Net income | -14.29M | -13.00M | -18.40M | 47.76M | -35.10M |
| Change in cash | -2.97M | 3.14M | -14.55M | 7.61M | -14.61M |
| Begin period cash flow | 8.86M | 5.72M | 20.27M | 12.66M | 27.27M |
| End period cash flow | 5.89M | 8.86M | 5.72M | 20.27M | 12.66M |
| Total cash from operating activities | -11.36M | -12.68M | -17.49M | -28.33M | -30.00M |
| Issuance of capital stock | - | 0.00M | 8.86M | 8.22M | 50.28M |
| Depreciation | -0.14M | -0.12M | 0.31M | 1.65M | 1.97M |
| Change to inventory | - | 0.00M | 0.06M | -0.11M | -0.29M |
| Change to account receivables | - | - | -0.19M | -0.15M | 0.47M |
| Sale purchase of stock | - | - | -0.02M | -0.32M | -0.25M |
| Other cashflows from financing activities | 22.74M | 12.04M | -0.02M | -0.06M | -0.25M |
| Capital expenditures | 0.00M | 0.00M | 0.10M | 0.36M | 1.83M |
| Change in working capital | 1.08M | -0.22M | -1.54M | -1.39M | 0.20M |
| Stock based compensation | 0.70M | 0.99M | 1.73M | 2.89M | 4.61M |
| Other non cash items | 1.29M | -0.32M | -1.79M | -84.95M | -2.50M |
| Free cash flow | -11.36M | -12.68M | -17.59M | -28.70M | -31.83M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TLPH Talphera Inc. |
0.04 3.96% |
1.05 | - | 1.02 | 61767.90 | 4.47 | 47287.19 | 0.11 |
| MKKGY Merck KGaA ADR |
-0.22 0.66% |
33.17 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-2.76 1.62% |
167.12 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.17 0.80% |
21.02 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
41.85 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. Vincent J. Angotti | CEO & Director | 1968 |
| Dr. Pamela Pierce Palmer M.D., Ph.D. | Co-Founder & Chief Medical Officer | 1963 |
| Mr. Raffi Mark Asadorian | Chief Financial Officer | 1969 |
| Mr. Anil N. Dasu | Chief Engineering Officer | 1963 |
| Dr. Shakil Aslam M.D. | Chief Medical Officer | 1965 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...